Uncertainty in CRISPR world and the start of more M&A
STAT reporters chat about the mood in the gene editing field, M&A deals in biotech, and leadership changes at Novo Nordisk.

What was the mood like at a big gene therapy conference last week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a good mood?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs.